Search our Database of Scientific Publications and Authors

I’m looking for a

    3405 results match your criteria Plaque Psoriasis

    1 OF 69

    Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).
    J Dermatol 2017 Jun 21. Epub 2017 Jun 21.
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
    The present study describes a subgroup analysis of 33 Japanese patients participating in UNCOVER-1, an international, placebo-controlled, phase 3 study of ixekizumab in patients with moderate-to-severe psoriasis. Patients were randomized to a placebo (n = 13) or ixekizumab 80 mg every 4 (IXEQ4W, n = 12) or 2 (IXEQ2W, n = 8) weeks, from week 0-12. At week 12, ixekizumab-treated patients with a static Physician Global Assessment score 0 or 1 (sPGA [0,1]; n = 16) were re-randomized to a placebo (n = 6), ixekizumab 80 mg every 12 (IXEQ12W, n = 5) or 4 (IXEQ4W, n = 5) weeks, from week 12-60. Read More

    Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial.
    Br J Dermatol 2017 Jun 21. Epub 2017 Jun 21.
    Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
    Background: Guselkumab, an anti-interleukin-23 monoclonal antibody, demonstrated significant efficacy in Phase 3 psoriasis trials.

    Objective: Evaluate the efficacy and safety of guselkumab in patients with moderate-to-severe plaque psoriasis with an inadequate response to ustekinumab.

    Methods: In this Phase 3, randomized, double-blind study, 871 patients received open-label ustekinumab (45mg or 90mg) at weeks 0 and 4. Read More

    IL-17 for therapy.
    J Dermatol Sci 2017 Jun 15. Epub 2017 Jun 15.
    Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, 55131, Germany.
    The cytokine IL-17 is now a target for an array of therapeutic monoclonal antibodies supposed to treat a variety of inflammatory diseases. The forerunner Secukinumab, an IL-17A neutralizing antibody, is meanwhile approved as first-line treatments for moderate-to-severe plaque psoriasis, and as second-line treatment for psoriatic arthritis and ankylosing spondylitis. Ixekizumab and Brodalumab, both also targeting the IL-17 pathway, were also recently approved by the FDA for plaque psoriasis. Read More

    TCR(+)CD3(+)CD4(-)CD8(-) effector T cells in psoriasis.
    Clin Immunol 2017 Jun 15. Epub 2017 Jun 15.
    Division of Pediatric Rheumatology and Immunology, Children's Hospital Dresden, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany; Department of Women's & Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK; Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, UK. Electronic address:
    The autoimmune/inflammatory disorder psoriasis is characterized by keratinocyte proliferation and immune cell infiltration of the skin. TCR(+)CD3(+)CD4(-)CD8(-) "double negative" (DN) T cells can derive from CD8(+) T cells through the down-regulation of CD8. The inhibitory molecule programmed death (PD-)1 is expressed on activated T cells and plays a role in the maintenance of peripheral tolerance. Read More

    [Psoriatic patients: Analysis of patients dissatisfied with their management].
    Ann Dermatol Venereol 2017 Jun 14. Epub 2017 Jun 14.
    Service de dermatologie, centre hospitalier Victor-Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95107 Argenteuil cedex, France.
    Background: The French are frequently regarded as grouchy. In a recent study, we observed a high proportion of patients initially consulting for psoriasis because they were dissatisfied with their previous therapy. We analyzed the characteristics of these patients. Read More

    Effect of psoriasis activity and topical treatment on plasma epidermal growth factor (EGF) and its soluble receptor (sEGFR).
    J Dermatolog Treat 2017 Jun 16:1-17. Epub 2017 Jun 16.
    a Department of Dermatology and Venereology , Medical University of Bialystok , Poland.
    Background: Pathogenesis of psoriasis involves epidermal growth factor (EGF) which participates in keratinocyte proliferation, angiogenesis and cell differentiation through binding to soluble epidermal growth factor receptor (sEGFR). It is synthesised by, among others, keratinocytes, especially within psoriatic skin.

    Objective: To evaluate EGF and sEGFR plasma concentrations during topical psoriatic treatment. Read More

    Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications.
    Cold Spring Harb Perspect Biol 2017 Jun 15. Epub 2017 Jun 15.
    Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261.
    The cytokines of the interleukin 17 (IL-17) family play a central role in the control of infections, especially extracellular fungi. Conversely, if unrestrained, these inflammatory cytokines contribute to the pathology of numerous autoimmune and chronic inflammatory conditions. Recent advances have led to the approval of IL-17A-blocking biologics for the treatment of moderate to severe plaque psoriasis, but much remains to be understood about the biological functions, regulation, and signaling pathways downstream of these factors. Read More

    Visual Loss Induced by Adalimumab Used for Plaque Psoriasis.
    Case Rep Dermatol 2017 Jan-Apr;9(1):60-64. Epub 2017 Mar 3.
    Maimonides Medical Center, Brooklyn, New York, USA.
    A 61-year-old Caucasian male with severe plaque psoriasis without joint involvement was initiated on adalimumab therapy. Shortly thereafter he presented to the emergency room with acute loss of vision in the right eye. A comprehensive systemic workup was instituted which included magnetic resonance imaging (MRI) with and without gadolinium of the brain and orbits. Read More

    Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.
    J Dermatolog Treat 2017 Jun 13:1-25. Epub 2017 Jun 13.
    c Analysis Group , Boston , MA , USA.
    Background: Biologics have been shown to improve the outcomes of patients with psoriasis but their cost is an issue.

    Objective: Determine the number needed to treat (NNT) to achieve a 75%/90% reduction in the Psoriasis Area and Severity Index (PASI-75/90) and evaluate the incremental cost per PASI-75/90 responder (CPR) relative to placebo in Japan.

    Methods: A network meta-analysis was conducted to estimate the relative probabilities of achieving PASI-75/90 and NNTs. Read More

    Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
    J Eur Acad Dermatol Venereol 2017 Jun 11. Epub 2017 Jun 11.
    University of Texas Health Science Center for Clinical Studies, Houston, TX, United States.
    Background: Psoriasis can greatly impact patients' lives by influencing clothing worn as well as by impairing sexual functioning. Secukinumab, a human monoclonal antibody selectively neutralizing interleukin-17A, has demonstrated good efficacy and safety in the treatment of moderate-to-severe psoriasis and psoriatic arthritis with a rapid onset of action and sustained response.

    Objective: This analysis using the CLEAR study, a phase 3b double-blind study comparing the efficacy and safety of secukinumab versus ustekinumab in adults with moderate-to-severe plaque psoriasis, evaluated the treatment effects on patient's daily activities and personal relationships. Read More

    Comparative evaluation of efficacy and safety of calcipotriol versus tacalcitol ointment, both in combination with NBUVB phototherapy in the treatment of stable plaque psoriasis.
    Photodermatol Photoimmunol Photomed 2017 Jun 11. Epub 2017 Jun 11.
    pt B.D Sharma Pgims, Rohtak, India.
    Background: Vitamin D analogues and NBUVB phototherapy are both well-established modalities of treatment in psoriasis. The objective of this open label, intra individual, left right study was to compare two different Vitamin D analogues, calcipotriol and tacalcitol, in combination with NBUVB phototherapy in chronic stable plaque psoriasis.

    Methods: Thirty patients with stable plaque psoriasis were enrolled for a 12 week clinical trial. Read More

    Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a Phase 3b, randomized, double-blinded, active-controlled, multicenter study (PSTELLAR).
    Br J Dermatol 2017 Jun 10. Epub 2017 Jun 10.
    Dermatology, University of Utah, Salt Lake City, UT, USA.
    Background: Phase 3 studies showed some patients maintained response for ≥6 months post-ustekinumab discontinuation.

    Objectives: To assess clinical responses with extended ustekinumab maintenance dosing intervals.

    Methods: Adults with moderate-to-severe plaque psoriasis received ustekinumab (45mg/90mg for weight ≤100 kg/>100 kg) at Week0, Week4, Week16 during open-label treatment. Read More

    Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Lancet 2017 Jun 5. Epub 2017 Jun 5.
    Harvard Medical School, Boston, MA, USA.
    Background: Tildrakizumab is a high-affinity, humanised, IgG1 κ antibody targeting interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis. Previous research suggested clinical improvement with inhibition of interleukin 23 p19. We did two phase 3 trials to investigate whether tildrakizumab is superior to placebo and etanercept in the treatment of chronic plaque psoriasis. Read More

    Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients.
    J Eur Acad Dermatol Venereol 2017 Jun 6. Epub 2017 Jun 6.
    Department of Dermatology, Larrey Hospital and Toulouse University, Toulouse, France.
    Background: Biological agents targeting IL-17 are very effective for clearing moderate to severe psoriasis. There is limited information regarding the frequency and pattern of psoriasis relapse upon treatment cessation.

    Objective: To investigate the pattern of psoriasis recurrence in patients who were treated with brodalumab following Amgen's decision to stop the clinical program in June 2015. Read More

    Serum fatty acid profile in psoriasis and its comorbidity.
    Arch Dermatol Res 2017 Jul 5;309(5):371-380. Epub 2017 Jun 5.
    Department of Dermatology and Venereology, Medical University of Bialystok, Żurawia str. 14, 15-540, Białystok, Poland.
    Psoriasis is a chronic inflammatory skin disease that is accompanied by metabolic disturbances and cardio-metabolic disorders. Fatty acids (FAs) might be a link between psoriasis and its comorbidity. The aim of the study was to evaluate serum concentrations of FAs and to investigate their association with the disease activity, markers of inflammation and possible involvement in psoriatic comorbidity: obesity, type 2 diabetes and hypertension. Read More

    Secukinumab is Superior to Fumaric Acid Esters in Treating Subjects with Moderate to Severe Plaque Psoriasis who are Naïve to Systemic Treatments: Results from the Randomized Controlled PRIME Trial.
    Br J Dermatol 2017 Jun 5. Epub 2017 Jun 5.
    Dermatologikum Hamburg, Hamburg, Germany.
    Background: Secukinumab is a fully human antibody that neutralizes IL-17A and has significant efficacy and a favorable safety profile in moderate to severe plaque psoriasis and psoriatic arthritis.

    Methods: In this 24-week, randomized, open-label, multicenter study with blinded assessment, subjects with moderate to severe plaque psoriasis, naïve to systemic treatments, were randomized to receive secukinumab 300 mg subcutaneously or oral fumaric acid esters (FAE). The primary objective was ≥75% improvement from Baseline Psoriasis Area and Severity Index (PASI) score (PASI 75 response) at Week 24 and missing subjects were considered responders if they were responders at the time of drop-out. Read More

    Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate to Severe Psoriasis up to 3 Years of Treatment: Results from A Double-Blind Extension Study.
    Br J Dermatol 2017 Jun 5. Epub 2017 Jun 5.
    Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany.
    Background: Secukinumab has demonstrated significant efficacy with a good safety profile through 1 year in plaque psoriasis. Given the chronic nature of this disease, long-term follow-up is needed to fully evaluate psoriasis therapies.

    Objectives: Determine long-term (3-year) efficacy/safety of secukinumab in moderate-to-severe psoriasis. Read More

    Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12 week results from two Phase 3 trials.
    J Eur Acad Dermatol Venereol 2017 Jun 2. Epub 2017 Jun 2.
    Department of Dermatology, Radboud University Nijmegen, Nijmegen, Netherlands.
    Background: Psoriasis symptoms may decrease quality of life for patients. Skin-related personal relationship difficulties in psoriasis patients are common, under-reported, and poorly understood.

    Objective: To assess the effect of ixekizumab (IXE) treatment on skin-related personal relationship difficulties in patients with moderate-to-severe psoriasis. Read More

    Prolongation of biologic dosing intervals in patients with stable psoriasis: a feasibility study.
    Ther Drug Monit 2017 May 31. Epub 2017 May 31.
    1Hospital Pharmacy; Departments of Dermatology; and2Immunology; Erasmus MC, University Medical Center Rotterdam, The Netherlands,3Department of R&D, Sanquin Reagents;4Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, Amsterdam, The Netherlands.
    Background: Biologics are usually licensed according to the "one dose fits all" principle. It is therefore suspected that a significant number of psoriasis patients are overtreated. However, evidence for successful dose reduction of biologics in psoriasis is scarce. Read More

    The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study.
    J Dermatol Sci 2017 May 16. Epub 2017 May 16.
    Pfizer Ltd., Tadworth, United Kingdom. Electronic address:
    Background: Tofacitinib is an oral Janus kinase inhibitor.

    Objective: This study assessed tofacitinib efficacy and safety vs placebo in Asian patients with moderate to severe chronic plaque psoriasis.

    Methods: Patients from China mainland, Taiwan, and Korea were randomized 2:2:1:1 to tofacitinib 5mg (N=88), tofacitinib 10mg (N=90), placebo→5mg (N=44), or placebo→10mg (N=44), twice daily (BID) for 52 weeks. Read More

    Influence of TNF alpha inhibitors and fumaric acid esters on male fertility in psoriasis patients.
    J Eur Acad Dermatol Venereol 2017 May 30. Epub 2017 May 30.
    Department of Dermatology, University Hospital of Erlangen, Erlangen, Germany.
    Objective: Is there any influence of a therapy with TNF alpha inhibitors or fumaric acid esters and of disease activity status on male fertility and sperm quality in psoriasis patients?.

    Methods: In this monocentric, open-label, prospective study, semen samples were collected from patients receiving either TNF alpha inhibitors or fumaric acid esters for moderate to severe plaque psoriasis. Semen was analysed at baseline before onset of the systemic therapy and monitored every three months under therapy. Read More

    Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis.
    J Eur Acad Dermatol Venereol 2017 May 27. Epub 2017 May 27.
    Kyowa Kirin Pharmaceutical Development, Inc., Princeton, NJ, USA.
    Background: OX40 (CD134) is expressed in lesional but not healthy skin of patients with psoriasis. KHK4083 is a fully human monoclonal antibody against OX40.

    Objective: The primary aim of this first-in-human phase 1 study was to determine the safety and tolerability of ascending single doses of KHK4083 in patients with mild to moderate plaque psoriasis. Read More

    Atorvastatin as adjunctive therapy for chronic plaque type psoriasis versus betamethasone valerate alone: A randomized, double-blind, placebo-controlled trial.
    Indian J Dermatol Venereol Leprol 2017 Jul-Aug;83(4):441-447
    Department of Medicine, Section of Dermatology, University of the Philippines-Philippine General Hospital, Manila, Philippines.
    Background: Psoriasis is a T helper 1 cell-mediated chronic inflammation. Statins have been found to have anti-inflammatory and immunomodulatory effects targeting T helper 1 cells and thus, are being investigated as treatments for psoriasis.

    Aims: To investigate the efficacy and safety of atorvastatin as adjunctive treatment for mild to moderate chronic plaque psoriasis; and the impact of atorvastatin on quality of life. Read More

    Glycemic Control in the Treatment of Psoriasis.
    Dermatology 2017 May 25. Epub 2017 May 25.
    School of Medicine, Department of Medicine, Queen's University, Kingston, ON, Canada.
    Psoriasis is a common chronic inflammatory skin disease that manifests as scaly erythematous plaques as a consequence of keratinocyte hyperproliferation and inflammation. It is commonly associated with diabetes, obesity, and the metabolic syndrome. While there are numerous approved treatment options available, they have limitations including availability, toxicities such as immunosuppression, and high cost. Read More

    Severe pellagra masked by concurrent plaque psoriasis: a case report of a hidden diagnosis.
    Dermatol Online J 2017 May 15;23(5). Epub 2017 May 15.
    Department of Dermatology, School of Medicine, University of California, Davis, Sacramento, California.
    Despite characteristic features, psoriasis can mimic other dermatologic conditions, such as seborrheic dermatitis, lichen simplex chronicus, and certain nutritional deficiencies such as pellagra. We present a patient with a longstanding history of severe plaque psoriasis who presented with disfiguring scaly plaques involving greater than 80% body surface area. The patient's disease was minimally responsive to multiple therapies. Read More

    Use of an oral phosphodiesterase-4 inhibitor (apremilast) for the treatment of chronic, severe atopic dermatitis: a case report.
    Dermatol Online J 2017 May 15;23(5). Epub 2017 May 15.
    University of Vermont College of Medicine, Burlington, Vermont.
    Atopic dermatitis (AD) is a common inflammatory dermatosis characterized by pruritus, erythema, induration, and lichenification. Current treatment options for generalized atopic dermatitis are limited and have potentially serious adverse effects, especially in patients with severe, chronic AD who frequently require systemic anti-inflammatory agents. Apremilast, an oral phosphodiesterase-4 inhibitor, was FDA approved in September 2014 for the treatment of moderate-to-severe plaque psoriasis. Read More

    The management of moderate-to-severe chronic plaque psoriasis.
    G Ital Dermatol Venereol 2017 May 23. Epub 2017 May 23.
    Dermatology Department, University of Pisa, Pisa, Italy -
    Recent approval and marketization of novel treatments have widened the range of therapeutic opportunities for moderate-to-severe psoriasis. In the next years, this panorama will be further enlarged as many other agents, both oral small molecules and biologics, have passed phase III and are expected to be approved, and subsequently marketed, shortly. In spite of this array of therapeutic possibilities, there is still an unmet need for an appropriate treatment in a large number of cases. Read More

    Expression of Angiogenic Factors in Psoriasis Vulgaris.
    J Clin Diagn Res 2017 Mar 1;11(3):EC23-EC27. Epub 2017 Mar 1.
    Resident, Department of Pathology, Coimbatore Medical College and Hospital, Coimbatore, Tamil Nadu, India.
    Introduction: Psoriasis is a chronic inflammatory skin disease characterized by epidermal hyperproliferation, abnormal differentiation and inflammatory infiltration in the dermis. The dermal microvascular expansion associated with abnormal orientation and dilatation of capillaries in the biopsies of the psoriatic skin suggest that the disease is dependent on angiogenesis.

    Aim: To analyze and compare the immunohistochemical expression of angiogenic factors - Vascular Endothelial Growth Factor (VEGF), von Willebrand Factor (vWF) and CD 34 in skin biopsies of psoriasis cases with control skin samples; and to correlate the expression of angiogenic factors with Psoriasis Area and Severity Clinical Index (PASI SCORE). Read More

    Paraoxonases and psoriasis: negative imbalance of anti--oxidant endogenous mechanisms.
    G Ital Dermatol Venereol 2017 May 16. Epub 2017 May 16.
    Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy -
    Backgroung: Numerous reports have shown that psoriasis patients are more exposed to lipoprotein peroxidation and to a decrease in the activity of paraoxonase (PON)1, an anti-oxidant and anti-inflammatory enzyme. Thus, it has been suggested that malfunction of the anti-oxidant system and an increased production of reactive oxygen species drive immune inflammatory events, that result in progressive skin cell damage in patients with psoriasis. The PON protein family, including PON1, PON2 and PON3, is one of the most important endogenous defense mechanisms against oxidative stress. Read More

    No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab.
    Br J Dermatol 2017 May 16. Epub 2017 May 16.
    Department of Dermatology, Instituto de Investigación Sanitaria Princesa (IIS-IP), Hospital Universitario la Princesa, Madrid, Spain.
    Ustekinumab is a human monoclonal antibody directed against the p40 subunit of both interleukin (IL)-12 and IL-23(1) . It has shown to be very effective in the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis with a good safety profile(2,) .In the last ten years, the appearance of antinuclear antibodies (ANA) and the induction of autoimmune diseases during treatment with tumour necrosis factor-alpha (TNFα) inhibitors has been described (3-4) . Read More

    Long-term treatment of chronic plaque psoriasis with biological drugs can control platelet activation: targeting the bridge between inflammation and atherothrombosis.
    Postepy Dermatol Alergol 2017 Apr 13;34(2):131-137. Epub 2017 Apr 13.
    Department of Dermatology, Medical University of Lodz, Lodz, Poland.
    Introduction: Platelet activation is elevated in moderate to severe psoriasis, and the reduction in platelet activation during short-term treatment has already been demonstrated. Soluble P-selectin is a well-established marker of platelet activation.

    Aim: To show whether the long-term treatment of psoriasis with biological drugs can reduce elevated platelet activation. Read More

    Topical 0.25% desoximetasone spray efficacy for moderate to severe plaque psoriasis: a randomized clinical trial.
    J Dermatolog Treat 2017 May 30:1-4. Epub 2017 May 30.
    a Department of Dermatology, Wake Forest School of Medicine , Center for Dermatology Research , Winston-Salem , NC , USA.
    Background: Traditionally, ointments were the vehicle of choice for psoriasis. Poor adherence of traditional vehicles limits the use of topical corticosteroids. Alternative formulations have gained popularity due to their ease of application, improved adherence and efficacy. Read More

    Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
    Lancet 2017 Jun 11;389(10086):2304-2316. Epub 2017 May 11.
    Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address:
    Background: TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but are expensive therapies. The aim of NOR-SWITCH was to examine switching from originator infliximab to the less expensive biosimilar CT-P13 regarding efficacy, safety, and immunogenicity.

    Methods: The study is a randomised, non-inferiority, double-blind, phase 4 trial with 52 weeks of follow-up. Read More

    Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis. Data from the Psobiosimilars registry.
    Br J Dermatol 2017 May 12. Epub 2017 May 12.
    Department of Medicine, Section of Dermatology and Venereology, University of Verona, Italy.
    Infliximab is a chimeric human-murine monoclonal antibody that is very effective in chronic plaque psoriasis reaching a Psoriasis Area and Severity Index (PASI) 75 response in 80.4% of patients at week 10.(1) The more common adverse events include infusion reactions and upper respiratory tract infections. Read More

    Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.
    Br J Dermatol 2017 May 12. Epub 2017 May 12.
    Dalhousie University, Halifax, NS, Canada.
    Clinical trials of biologic therapies in psoriasis usually evaluate fixed dosing regimens. It is well-known, however, that patients prescribed biologics may occasionally need to interrupt therapy for reasons such as surgery, changes in healthcare coverage, or pregnancy.(1) Consequently, dermatologists need to know whether interruption of biologic therapy may be associated with diminished response upon retreatment. Read More

    Serum YKL-40 as a potential biomarker of inflammation in psoriasis.
    J Dermatolog Treat 2017 May 30:1-5. Epub 2017 May 30.
    a Department of Dermatology and Venereology , Medical University of Bialystok , Bialystok , Poland.
    Objective: YKL-40 is an inflammatory glycoprotein associated with atherosclerosis, cardiovascular disease, diabetes or metabolic syndrome which are common comorbidities in psoriasis. The aim of the study was to assess serum YKL-40 level in psoriasis and elucidate possible associations with disease activity, inflammatory or metabolic parameters and treatment.

    Methods: A total of 37 individuals with active plaque-type psoriasis and 15 healthy controls were enrolled. Read More

    What is clearance worth? Patients' stated risk tolerance for psoriasis treatments.
    J Dermatolog Treat 2017 Jun 7:1-7. Epub 2017 Jun 7.
    d Eli Lilly and Company , Indianapolis , IN , USA.
    Purpose: The purpose of this study was to provide quantitative evidence of patients' tolerance for therapeutic risks associated with psoriasis treatments that could offer psoriasis improvements beyond the PASI 75 benchmark.

    Materials And Methods: We used a discrete-choice experiment in which respondents chose between competing psoriasis treatments characterized by benefits (i.e. Read More

    Desoximetasone 0.25% spray, adrenal suppression and efficacy in extensive plaque psoriasis.
    J Dermatolog Treat 2017 May 31:1-3. Epub 2017 May 31.
    a Department of Dermatology , Center for Dermatology Research, Wake Forest School of Medicine , Winston-Salem , NC , USA.
    Background: In extensive psoriasis, topical corticosteroids are generally only used to supplement phototherapy and systemic therapy. Spray formulations are easier than other vehicle preparations to apply and may be an option for treating extensive psoriasis.

    Objective: To evaluate the potential for hypothalamic-pituitary-adrenal axis suppression and efficacy of topical desoximetasone 0. Read More

    Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics.
    J Dermatol 2017 May 11. Epub 2017 May 11.
    Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
    Recent studies indicate the presence of systemic inflammation in psoriatic patients, and this inflammatory status is significantly associated with a range of comorbidities. The aim of this study was to evaluate the clinical significance of novel inflammatory biomarkers, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and mean platelet volume (MPV) in Japanese patients with plaque-type psoriasis (PsV) and psoriatic arthritis (PsA). One hundred and eighty-six patients with PsV and 50 patients with PsA treated with biologics, including infliximab, adalimumab and ustekinumab, were retrospectively analyzed before and after treatment. Read More

    Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study.
    J Dermatol 2017 May 11. Epub 2017 May 11.
    Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
    The efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has been evaluated for moderate to severe plaque psoriasis in global trials which have included a low proportion of Asian subjects. We analyzed the efficacy and safety of secukinumab in Taiwanese patients in a phase III global clinical trial (ERASURE). Fifty-one Taiwanese patients were randomized into s. Read More

    Narrowband ultraviolet B light treatment changes plasma concentrations of MMP-3, MMP-9 and TIMP-3 in psoriatic patients.
    Ther Clin Risk Manag 2017 27;13:575-582. Epub 2017 Apr 27.
    Department of Esthetic Medicine.
    Background: Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are thought to be associated with the pathogenesis and spread of psoriatic disease. This study was designed to investigate the plasma levels of MMP-3, MMP-9 and TIMP-3 in plaque psoriasis patients prior to and following a course of ultraviolet B narrowband treatment with respect to disease advancement.

    Methods: Plasma samples of 49 patients suffering from plaque psoriasis and 40 healthy volunteers were evaluated. Read More

    Biologics and Dermatology Life Quality Index (DLQI) in the Australasian Psoriasis Population.
    J Dermatolog Treat 2017 May 10:1-18. Epub 2017 May 10.
    a Skin and Cancer Foundation Inc , Carlton , Victoria , Australia.
    Background/objectives: Psoriasis is a chronic condition that may require long-term treatment for disease control. This analysis utilises data from the Australasian Psoriasis Registry with particular attention to the impact of biologic therapy on DLQI, and the differences between the biologics in terms of DLQI score change.

    Methods: A retrospective review of patients enrolled in the Australasian Psoriasis Registry from April 2008 to August 2016 was conducted. Read More

    1 OF 69